Coronary disease & ACS

Association Between Myocardial Infarction and Quality of Life in the ISCHEMIA Trial

JACC Cardiovasc IntervPublished Secondary analysis of the ISCHEMIA randomised trial

Authors' conclusion

In ISCHEMIA, SMI was associated with reductions in both early and late generic and disease-specific QoL, whereas PMI was only associated with a transient reduction in disease-specific QoL.

Study context

Population
Randomised patients in the ISCHEMIA trialprimary analysis population
Participants
4,375 patients
Comparison
PMI and SMI vs no myocardial infarction (MI)
  • PMIn = 84
  • SMIn = 352
Methodological detailsMedian follow-up 36.2 months (Q1-Q3: 23.8-49.5 months)
  • Median follow-up 36.2 months (Q1-Q3: 23.8-49.5 months)

Primary result

As reported in the abstract

Adjusted difference in quality of life (QoL) after MI
Adjusted difference, points (95% CI)
SMIearly EQ-5D VAS
−5.7(−7.3 to −4.1)
SMIlate EQ-5D VAS
−3.1(−4.3 to −1.9)
SMIearly SAQ-7
−7.7(−9.4 to −6.1)
SMIlate SAQ-7
−1.9(−3.2 to −0.7)
PMIearly EQ-5D VAS
−0.8(−3.3 to 1.8)
PMIlate EQ-5D VAS
−0.7(−2.7 to 1.2)
PMIearly SAQ-7
−3.0(−5.7 to −0.4)
PMIlate SAQ-7
−0.2(−2.2 to 1.8)

Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.

Original publication

Association Between Myocardial Infarction and Quality of Life in the ISCHEMIA Trial. JACC Cardiovasc Interv. Published 23 April 2025. doi:10.1016/j.jcin.2025.02.011

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.